Parameter

Geometric
Leiden University, Leiden, The Netherlands Introduction: Reliable methods to quantify skin lesions are critical for the evaluation of disease severity and assessment of therapeutic response. In dermatological trials often two dimensional digital photography is utilized which has inherent disadvantages. It appears that high-resolution three-dimensional (3D) imaging may offer many advantages such as offline 3D visualization and automatic picture segmentation resulting in an objective and detailed skin lesion characterization. At present this technique is not optimally technical and analytical validated which is a pre-requisite for clinical application.
Material and Methods:
In this study we investigated the performance and clinical use of the 3D skin-imaging LifeViz™ system (Quantificare, Sophia Antipolis, France) in conjunction with the DermaPix Software. The validation of the LifeViz Micro was conducted with four trained operators that captured a synthetic phantom object on three different skin backgrounds at four time points during a period of one week. Results: Coefficient of variations for volume of the 3D system were 1.0%, 2.6% and 1.4% for inter-operator, skin background and interday variability, respectively. The overall precision of the system was 2.7% for volume, 1.6% for diameter and 4.1% for height. In order to determine accuracy of the system, a ruler was photographed and a mean error of 0.3% (range 0.0-0.8%) was observed. Preliminary data on cutaneous lesions also show low inter-observer variability and accurate images. Conclusions: This validation study demonstrates that this novel 3D-imaging system is precise and objectively quantifies a phantom object representing a skin lesion. The results support clinical use of this technology enabling high-resolution computation. Also the accuracy results are promising, but needs to be extended with accuracy assessment of absolute measurements. The preliminary clinical data suggest that application of this non-invasive imaging technique is suitable to quantitatively measure characteristics of cutaneous lesions and may be a promising tool in clinical trials. Material and Methods: A retrospective, cross-sectional register study was conducted, covering four months in 2010. Data from the Prescribed Drug Register on all dispensed drug prescriptions in Swedish pharmacies from January 1 to April 30 were linked to the drug-drug interaction database SFINX. The analysis focused on drug interactions classified in the database as clinically relevant that can be handled, e.g. by dose adjustments (C-interactions), and clinically relevant interactions that should be avoided (D-interactions). Interactions were categorized according to clinical consequence and drug type and prevalences of interacting drug combinations were described. The study was approved by the Regional Ethics Committee. Results: About half of the population were dispensed at least one drug prescription. Mean (SD) number of dispensed drugs was 3.8 (3.4). About 2.5 million potentially interacting drug combinations were identified in the study population of 9.3 million people. Among detected interactions 38% were classified as C-interactions and 3.8% Uracil catabolism is crucial for the pharmacokinetics of the chemotherapeutic 5-fluorouracil (5-FU) since 5-FU is degraded by the same pathway. Decreased activity of the first catabolizing enzyme, dihydropyrimidine dehydrogenase (DPD), is a major predictor of 5-FU toxicity with known risk variants in the DPD gene (DPYD) accounting for ~30% of toxicities. However, not all toxicity cases can be explained by DPYD risk variants. To date, the phenotypic variability in the catabolism downstream of DPD by dihydropyrimidinase (DHP) and β -ureidopropionase (bUP), potentially contributing to 5-FU toxicity, has not been investigated. Thus, we aimed to characterize the baseline phenotypic variability of endogenous metabolites and metabolic ratios of 5-FU catabolism enzymes and to correlate the phenotype with genetic variation in the DHP and bUP genes (DPYS and UPB1).
ThERAPy ADhEREnCE In ElDERly oF noRThERn PoRTuGAl
ChARACTERIzATIon oF uRACIl CATAbolISM VARIAbIlITy In hEAlThy VolunTEERS
Material and Methods:
Three variants in DPYS and UPB1 previously associated with 5-FU toxicity were genotyped in 320 healthy volunteers and their plasma uracil, dihydrouracil (UH 2 ), β -ureidopropionic acid (UPA), and β -alanine (BAL) concentrations were determined by LC-MS/MS. Results and Conclusions: High inter-individual variability in all metabolic ratios was observed. Sex-dependent differences were detected at each enzymatic step in the uracil catabolism pathway, with lower metabolite levels (P ≤ 0.007) in women. Moreover, lower UPA/UH 2 ratios (P < 0.001) were observed in women, suggesting that reduced 5-Fluoro-UH 2 catabolism may contribute to higher fluoropyrimidine toxicity rates observed in females. Furthermore, volunteers carrying DPYS variant c.265-58T> C had lower UH 2 plasma levels (P = 0.033) and higher UPA/UH 2 ratios (P = 0.036) and carriers of the UPB1 variant c.1-80C> G showed lower BAL plasma levels (P = 0.004). These initial results are in agreement with the previously observed reduced fluoropyrimidine toxicity in c.265-58C carriers and increased toxicity in carriers of c.1-80G, indicating a possible functional effect related to these variants.
